SpringWorks Therapeutics, Inc.
NASDAQ:SWTX
33.09 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | SpringWorks Therapeutics, Inc. |
Symbool | SWTX |
Munteenheid | USD |
Prijs | 33.09 |
Beurswaarde | 2,457,693,570 |
Dividendpercentage | 0% |
52-weken bereik | 18 - 53.92 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Saqib Islam J.D. |
Website | https://www.springworkstx.com |
An error occurred while fetching data.
Over SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)